PMID- 30916194
OWN - NLM
STAT- MEDLINE
DCOM- 20200225
LR  - 20200309
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Print)
IS  - 0066-782X (Linking)
VI  - 112
IP  - 3
DP  - 2019 Mar
TI  - Beta-Blocker Type Effect on Substrate Oxidation during HIIE in Heart Failure 
      Patients: Pilot Data.
PG  - 304-308
LID - S0066-782X2019000300304 [pii]
LID - 10.5935/abc.20190039 [doi]
AB  - The effect of third and second-generation type of beta-blocker on substrate 
      oxidation especially during high-intensity exercises are scarce. The objective of 
      the study is to explore differences of beta-blocker regimens (vasodilating vs. 
      non-vasodilating beta-blockers) for substrate oxidation during in high-intensity 
      intermittent exercise (HIIE) in chronic heart failure and reduced ejection 
      fraction (HFrEF). Eighteen CHF males (58.8 +/- 9 years), 8 under use of beta1 specific 
      beta-blockers+alfa 1-blocker and 10 using beta1 non-specific beta-blockers, were 
      randomly assigned to 4 different HIIE, in a cross-over design. The 4 protocols 
      were: 30 seconds (A and B) or 90 seconds (C and D) at 100% peak power output, 
      with passive (A and C) or active recovery (50% of PPO; B and D). Energy 
      expenditure (EE; kcal/min), quantitative carbohydrate (CHO) and lipid oxidation 
      (g/min) and qualitative (%) contribution were calculated. Two-way ANOVA and 
      Bonferroni post-hoc test were used (p-value </= 0.05) to compare CHO and lipid 
      oxidation at rest and at 10min. Total exercise time or EE did not show 
      differences for beta-blocker use. The type of beta-blocker use showed impact in 
      CHO (%) and lipid (g/min and %) for rest and 10 min, but absolute contribution of 
      CHO (g/min) was different just at 10min (Interaction p = 0.029). Higher CHO 
      oxidation was found in vasodilating beta-blockers when comparing to 
      non-vasodilating. According to our pilot data, there is an effect of beta-blocker 
      type on substrate oxidation during HIIE, but no influence on EE or exercise total 
      time in HFrEF patients.
FAU - Ribeiro, Paula Aver Bretanha
AU  - Ribeiro PAB
AUID- ORCID: 0000-0003-0513-5812
AD  - Cardiovascular Prevention and Rehabilitation Centre (EPIC), Montreal Heart 
      Institute, Montreal, Quebec - Canada.
AD  - Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, 
      Quebec - Canada.
AD  - Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul 
      (UFRS), Porto Alegre, RS - Brazil.
FAU - Normandin, Eve
AU  - Normandin E
AD  - Cardiovascular Prevention and Rehabilitation Centre (EPIC), Montreal Heart 
      Institute, Montreal, Quebec - Canada.
AD  - Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, 
      Quebec - Canada.
AD  - Faculty of Physical Education and Sports, University of Sherbrooke, Sherbrooke, 
      Quebec - Canada.
FAU - Meyer, Philippe
AU  - Meyer P
AD  - Division of Cardiology, University Hospital, Faculty of Medicine, University of 
      Geneva, Geneva - Switzerland.
FAU - Juneau, Martin
AU  - Juneau M
AD  - Cardiovascular Prevention and Rehabilitation Centre (EPIC), Montreal Heart 
      Institute, Montreal, Quebec - Canada.
AD  - Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, 
      Quebec - Canada.
FAU - White, Michel
AU  - White M
AD  - Cardiovascular Prevention and Rehabilitation Centre (EPIC), Montreal Heart 
      Institute, Montreal, Quebec - Canada.
AD  - Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, 
      Quebec - Canada.
FAU - Nigam, Anil
AU  - Nigam A
AD  - Cardiovascular Prevention and Rehabilitation Centre (EPIC), Montreal Heart 
      Institute, Montreal, Quebec - Canada.
AD  - Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, 
      Quebec - Canada.
FAU - Gayda, Mathieu
AU  - Gayda M
AD  - Cardiovascular Prevention and Rehabilitation Centre (EPIC), Montreal Heart 
      Institute, Montreal, Quebec - Canada.
AD  - Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, 
      Quebec - Canada.
LA  - eng
LA  - por
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
RN  - 0 (Adrenergic beta-Antagonists)
SB  - IM
MH  - Adrenergic beta-Antagonists/metabolism/*pharmacology
MH  - Aged
MH  - Carbohydrate Metabolism/*physiology
MH  - Cross-Over Studies
MH  - Energy Metabolism/*drug effects
MH  - Exercise/*physiology
MH  - Heart Failure/metabolism/*physiopathology
MH  - High-Intensity Interval Training/*methods
MH  - Humans
MH  - Lipid Metabolism/physiology
MH  - Male
MH  - Middle Aged
MH  - Ventricular Function, Left/physiology
PMC - PMC6424045
COIS- Potential Conflict of Interest No potential conflict of interest relevant to this 
      article was reported.
EDAT- 2019/03/28 06:00
MHDA- 2020/02/26 06:00
PMCR- 2019/03/01
CRDT- 2019/03/28 06:00
PHST- 2018/01/27 00:00 [received]
PHST- 2018/08/15 00:00 [accepted]
PHST- 2019/03/28 06:00 [entrez]
PHST- 2019/03/28 06:00 [pubmed]
PHST- 2020/02/26 06:00 [medline]
PHST- 2019/03/01 00:00 [pmc-release]
AID - S0066-782X2019000300304 [pii]
AID - 10.5935/abc.20190039 [doi]
PST - ppublish
SO  - Arq Bras Cardiol. 2019 Mar;112(3):304-308. doi: 10.5935/abc.20190039.